Hattapark Dejakaisaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hattapark Dejakaisaya has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Nigel Charles Jones
Department of Neuroscience Monash University Melbourne Victoria Australia
3 shared publications - Colin W. G. Fishwick
School of Chemistry, University of Leeds, Leeds LS2 9JT, UK
2 shared publications - Jonathan D. Lippiat
School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK
2 shared publications Nadia Pilati
Autifony Srl, Istituto di Ricerca Pediatrica Citta' della Speranza, Corso Stati Uniti, 4f, 35127 Padova, Italy
2 shared publications- Patrick Kwan
Department of Neuroscience, School of Translational Medicine Monash University Melbourne Victoria Australia
2 shared publications Rachel M. Johnson
School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK; Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
2 shared publications
Latest Publications
- 1 June 2026
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 31 (2) , 755-763
Early institutional experiences of awake craniotomy with tumor removal at Chulabhorn Hospital, Thailand
Background & Objective: Brain tumors in eloquent regions pose major surgical challenges due to the high risk of neurological deficits with conventional resection. Awake craniotomy mitigates these risks through intraoperative neurophysiological monitoring that helps preserve eloquent function. Yet its adoption and documentation in Thailand, and Southeast Asia more broadly, remain limited. This study aims to address this gap and support regional advancement and benchmarking of the technique. Methods: We implemented a structured awake craniotomy program at Chulabhorn Hospital using a standardized asleep–awake–asleep (AAA) protocol with rigid skull fixation, informed in part by training from The Royal Melbourne Hospital. Results: Eight patients with intracranial tumors in eloquent cortical areas underwent surgery under this protocol. One intraoperative and one postoperative seizure occurred. Motor function was preserved or improved in nearly all cases, with only a single instance of postoperative weakness. Language outcomes were stable in five patients and improved in three. Gross total resection was achieved in five procedures, while three achieved subtotal resections. There was no perioperative mortality, surgical site infection, or need for reoperation. Conclusions: These findings on one of the few documented series of awake craniotomy in Thailand demonstrate that this technique can be safely introduced and effectively performed within emerging neurosurgical centers in Southeast Asia. Our experience shows that a standardized AAA protocol is both safe and feasible for tumor resection in eloquent brain regions and provides an important foundational step toward expanding the technique and strengthening regional neurosurgical capacity.
- 1 June 2026
- Published by ASEAN Neurological Association in Neurology Asia
- Vol. 31 (2) , 755-763
Early institutional experiences of awake craniotomy with tumor removal at Chulabhorn Hospital, Thailand
Background & Objective: Brain tumors in eloquent regions pose major surgical challenges due to the high risk of neurological deficits with conventional resection. Awake craniotomy mitigates these risks through intraoperative neurophysiological monitoring that helps preserve eloquent function. Yet its adoption and documentation in Thailand, and Southeast Asia more broadly, remain limited. This study aims to address this gap and support regional advancement and benchmarking of the technique. Methods: We implemented a structured awake craniotomy program at Chulabhorn Hospital using a standardized asleep–awake–asleep (AAA) protocol with rigid skull fixation, informed in part by training from The Royal Melbourne Hospital. Results: Eight patients with intracranial tumors in eloquent cortical areas underwent surgery under this protocol. One intraoperative and one postoperative seizure occurred. Motor function was preserved or improved in nearly all cases, with only a single instance of postoperative weakness. Language outcomes were stable in five patients and improved in three. Gross total resection was achieved in five procedures, while three achieved subtotal resections. There was no perioperative mortality, surgical site infection, or need for reoperation. Conclusions: These findings on one of the few documented series of awake craniotomy in Thailand demonstrate that this technique can be safely introduced and effectively performed within emerging neurosurgical centers in Southeast Asia. Our experience shows that a standardized AAA protocol is both safe and feasible for tumor resection in eloquent brain regions and provides an important foundational step toward expanding the technique and strengthening regional neurosurgical capacity.
- Open Access
- 12 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0323863
Television watching and cognitive outcomes in adults and older adults: A systematic review and dose-response meta-analysis of observational studies
This systematic review and meta-analysis aimed to examine the association between television watching and cognitive outcomes in adults and older adults as the current evidence is inconsistent. We searched the Cochrane, MEDLINE, Embase, PsycINFO, Scopus, and Web of Science databases for relevant studies from inception to June 30, 2024. Risk of bias was assessed using the Newcastle–Ottawa Scale. Dose–response and conventional meta-analyses were performed using one-stage random-effects and DerSimonian and Laird random-effects models, respectively. Our systematic review included 35 studies with 1,292,052 participants (8,572 cases of cognitive impairment), of which 28 studies were further meta-analyzed. A dose–response meta-analysis revealed a nonlinear association between time spent watching TV and an increased risk of cognitive impairment (Wald test p-value = 0.04), particularly for viewing durations of ≥4 hours per day. Additionally, watching ≥6 hours of television per day was associated with a significant decrease in cognitive score (standardized beta coefficient = −0.09; 95% CI: −0.17, −0.003; I2 = 71.8%; seven studies). Also, a longer television-watching time was associated with a lower cognitive score (pooled standardized mean difference = −0.02; 95% CI: −0.03, −0.003; I2 = 66.45%; six studies). Watching television for a longer period was associated with negative cognitive outcomes in adults and older adults. Further research is needed to confirm this association and elucidate the underlying biological mechanisms.
- 12 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0323863
Open AccessTelevision watching and cognitive outcomes in adults and older adults: A systematic review and dose-response meta-analysis of observational studies
This systematic review and meta-analysis aimed to examine the association between television watching and cognitive outcomes in adults and older adults as the current evidence is inconsistent. We searched the Cochrane, MEDLINE, Embase, PsycINFO, Scopus, and Web of Science databases for relevant studies from inception to June 30, 2024. Risk of bias was assessed using the Newcastle–Ottawa Scale. Dose–response and conventional meta-analyses were performed using one-stage random-effects and DerSimonian and Laird random-effects models, respectively. Our systematic review included 35 studies with 1,292,052 participants (8,572 cases of cognitive impairment), of which 28 studies were further meta-analyzed. A dose–response meta-analysis revealed a nonlinear association between time spent watching TV and an increased risk of cognitive impairment (Wald test p-value = 0.04), particularly for viewing durations of ≥4 hours per day. Additionally, watching ≥6 hours of television per day was associated with a significant decrease in cognitive score (standardized beta coefficient = −0.09; 95% CI: −0.17, −0.003; I2 = 71.8%; seven studies). Also, a longer television-watching time was associated with a lower cognitive score (pooled standardized mean difference = −0.02; 95% CI: −0.03, −0.003; I2 = 66.45%; six studies). Watching television for a longer period was associated with negative cognitive outcomes in adults and older adults. Further research is needed to confirm this association and elucidate the underlying biological mechanisms.
- 3 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 102 (2) , 370-381
Effect of ceftriaxone on the glutamate-glutamine cycle and seizure susceptibility of Tg2576 mouse model of Alzheimer's disease
Background: Individuals with Alzheimer's disease (AD) have a heightened risk of epilepsy. However, the underlying mechanisms are not well-understood. Objective: We aimed to elucidate the role of the glutamate-glutamine cycle in this mechanism and test the effect of ceftriaxone, a glutamate transporter-1 (GLT-1) enhancer, on seizure susceptibility in the Tg2576 mouse model of AD. Methods: First, we assessed expression levels of key proteins in the glutamate-glutamine cycle in Tg2576 ( n = 7) and wild-type littermates ( n = 7), and subsequently in the kindling model of epilepsy ( n = 6) and sham ( n = 6). Then, kindling susceptibility was assessed in three groups: 200 mg/kg ceftriaxone-treated Tg2576 (Tg-Ceft, n = 9); saline-treated Tg2576 (Tg-Sal, n = 9); and saline-treated wild-type (WT-Sal, n = 15). Mice were treated for seven days before kindling, and seizure susceptibility compared between groups. Results: Protein levels of GLT-1 ( p = 0.0093) and glutamine synthetase ( p = 0.0016) were reduced in cortex of Tg2576 mice, compared to WT. Kindling increased GLT-1 (cortex: p < 0.0001, hippocampus: p = 0.0075), and glutaminase (cortex: p = 0.0044) protein levels, compared to sham. Both Tg-Ceft and WT-Sal displayed Class IV seizures in response to the first stimulation ( p > 0.99), while Tg-Sal displayed Class V seizure ( p = 0.0212 versus WT-Sal). Seizure susceptibility of Tg-Ceft was not different from Tg-Sal ( p > 0.05), and kindling rates did not differ between groups. Conclusions: Disruptions to key components of the glutamate-glutamine cycle are observed in models of AD and epilepsy. However, increasing GLT-1 through ceftriaxone treatment did not influence seizure susceptibility in Tg2576 mice, suggesting this is not an effective strategy to lower seizure susceptibility in AD, or a higher dosage is needed.
- 3 November 2024
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 102 (2) , 370-381
Effect of ceftriaxone on the glutamate-glutamine cycle and seizure susceptibility of Tg2576 mouse model of Alzheimer's disease
Background: Individuals with Alzheimer's disease (AD) have a heightened risk of epilepsy. However, the underlying mechanisms are not well-understood. Objective: We aimed to elucidate the role of the glutamate-glutamine cycle in this mechanism and test the effect of ceftriaxone, a glutamate transporter-1 (GLT-1) enhancer, on seizure susceptibility in the Tg2576 mouse model of AD. Methods: First, we assessed expression levels of key proteins in the glutamate-glutamine cycle in Tg2576 ( n = 7) and wild-type littermates ( n = 7), and subsequently in the kindling model of epilepsy ( n = 6) and sham ( n = 6). Then, kindling susceptibility was assessed in three groups: 200 mg/kg ceftriaxone-treated Tg2576 (Tg-Ceft, n = 9); saline-treated Tg2576 (Tg-Sal, n = 9); and saline-treated wild-type (WT-Sal, n = 15). Mice were treated for seven days before kindling, and seizure susceptibility compared between groups. Results: Protein levels of GLT-1 ( p = 0.0093) and glutamine synthetase ( p = 0.0016) were reduced in cortex of Tg2576 mice, compared to WT. Kindling increased GLT-1 (cortex: p < 0.0001, hippocampus: p = 0.0075), and glutaminase (cortex: p = 0.0044) protein levels, compared to sham. Both Tg-Ceft and WT-Sal displayed Class IV seizures in response to the first stimulation ( p > 0.99), while Tg-Sal displayed Class V seizure ( p = 0.0212 versus WT-Sal). Seizure susceptibility of Tg-Ceft was not different from Tg-Sal ( p > 0.05), and kindling rates did not differ between groups. Conclusions: Disruptions to key components of the glutamate-glutamine cycle are observed in models of AD and epilepsy. However, increasing GLT-1 through ceftriaxone treatment did not influence seizure susceptibility in Tg2576 mice, suggesting this is not an effective strategy to lower seizure susceptibility in AD, or a higher dosage is needed.
- Open Access
Astrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer's disease
Alzheimer's disease (AD) can increase the risk of epilepsy by up to 10‐fold compared to healthy age‐matched controls. However, the pathological mechanisms that underlie this increased risk are poorly understood. Because disruption in brain glutamate homeostasis has been implicated in both AD and epilepsy, this might play a mechanistic role in the pathogenesis of epilepsy in AD. Prior to the formation of amyloid beta (Aβ) plaques, the brain can undergo pathological changes as a result of increased production of amyloid precursor protein (APP) and Aβ oligomers. Impairments in the glutamate uptake ability of astrocytes due to astrogliosis are hypothesized to be an early event occurring before Aβ plaque formation. Astrogliosis may increase the susceptibility to epileptogenesis of the brain via accumulation of extracellular glutamate and resulting excitotoxicity. Here we hypothesize that Aβ oligomers and proinflammatory cytokines can cause astrogliosis and accumulation of extracellular glutamate, which then contribute to the pathogenesis of epilepsy in AD. In this review article, we consider the evidence supporting a potential role of dysfunction of the glutamate‐glutamine cycle and the astrocyte in the pathogenesis of epilepsy in AD.
Open AccessAstrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer's disease
Alzheimer's disease (AD) can increase the risk of epilepsy by up to 10‐fold compared to healthy age‐matched controls. However, the pathological mechanisms that underlie this increased risk are poorly understood. Because disruption in brain glutamate homeostasis has been implicated in both AD and epilepsy, this might play a mechanistic role in the pathogenesis of epilepsy in AD. Prior to the formation of amyloid beta (Aβ) plaques, the brain can undergo pathological changes as a result of increased production of amyloid precursor protein (APP) and Aβ oligomers. Impairments in the glutamate uptake ability of astrocytes due to astrogliosis are hypothesized to be an early event occurring before Aβ plaque formation. Astrogliosis may increase the susceptibility to epileptogenesis of the brain via accumulation of extracellular glutamate and resulting excitotoxicity. Here we hypothesize that Aβ oligomers and proinflammatory cytokines can cause astrogliosis and accumulation of extracellular glutamate, which then contribute to the pathogenesis of epilepsy in AD. In this review article, we consider the evidence supporting a potential role of dysfunction of the glutamate‐glutamine cycle and the astrocyte in the pathogenesis of epilepsy in AD.
- 19 April 2021
- Published by Springer Nature in Metabolomics
- Vol. 17 (5) , 1-12
Altered metabolic pathways in a transgenic mouse model suggest mechanistic role of amyloid precursor protein overexpression in Alzheimer’s disease
Introduction The mechanistic role of amyloid precursor protein (APP) in Alzheimer’s disease (AD) remains unclear. Objectives Here, we aimed to identify alterations in cerebral metabolites and metabolic pathways in cortex, hippocampus and serum samples from Tg2576 mice, a widely used mouse model of AD. Methods Metabolomic profilings using liquid chromatography-mass spectrometry were performed and analysed with MetaboAnalyst and weighted correlation network analysis (WGCNA). Results Expressions of 11 metabolites in cortex, including hydroxyphenyllactate—linked to oxidative stress—and phosphatidylserine—lipid metabolism—were significantly different between Tg2576 and WT mice (false discovery rate < 0.05). Four metabolic pathways from cortex, including glycerophospholipid metabolism and pyrimidine metabolism, and one pathway (sulphur metabolism) from hippocampus, were significantly enriched in Tg2576 mice. Network analysis identified five pathways, including alanine, aspartate and glutamate metabolism, and mitochondria electron transport chain, that were significantly correlated with AD genotype. Conclusions Changes in metabolite concentrations and metabolic pathways are present in the early stage of APP pathology, and may be important for AD development and progression.
- 19 April 2021
- Published by Springer Nature in Metabolomics
- Vol. 17 (5) , 1-12
Altered metabolic pathways in a transgenic mouse model suggest mechanistic role of amyloid precursor protein overexpression in Alzheimer’s disease
Introduction The mechanistic role of amyloid precursor protein (APP) in Alzheimer’s disease (AD) remains unclear. Objectives Here, we aimed to identify alterations in cerebral metabolites and metabolic pathways in cortex, hippocampus and serum samples from Tg2576 mice, a widely used mouse model of AD. Methods Metabolomic profilings using liquid chromatography-mass spectrometry were performed and analysed with MetaboAnalyst and weighted correlation network analysis (WGCNA). Results Expressions of 11 metabolites in cortex, including hydroxyphenyllactate—linked to oxidative stress—and phosphatidylserine—lipid metabolism—were significantly different between Tg2576 and WT mice (false discovery rate < 0.05). Four metabolic pathways from cortex, including glycerophospholipid metabolism and pyrimidine metabolism, and one pathway (sulphur metabolism) from hippocampus, were significantly enriched in Tg2576 mice. Network analysis identified five pathways, including alanine, aspartate and glutamate metabolism, and mitochondria electron transport chain, that were significantly correlated with AD genotype. Conclusions Changes in metabolite concentrations and metabolic pathways are present in the early stage of APP pathology, and may be important for AD development and progression.
- Open Access
Structure-based identification and characterisation of novel inhibitors of K Na 1.1 potassium channels, a stratified target for KCNT1 -related epilepsy
Several types of drug-resistant epileptic encephalopathies of infancy have been associated with mutations in the KCNT1 gene, which encodes the sodium-activated potassium channel subunit K Na 1.1. These mutations are commonly gain-of-function, increasing channel activity, therefore inhibition by drugs is proposed as a stratified approach to treat disorders. To date, quinidine therapy has been trialled with several patients, but mostly with unsuccessful outcomes, which has been linked to its low potency and lack of specificity. Here we describe the use of a cryo-electron microscopy-derived K Na 1.1 structure and mutational analysis to identify the quinidine biding site and identified novel inhibitors that target this site using computational methods. We describe six compounds that inhibit K Na 1.1 channels with low- and sub-micromolar potencies, likely through binding in the intracellular pore vestibule. In preliminary hERG inhibition and cytotoxicity assays, two compounds showed little effect. These compounds may provide starting points for the development of novel pharmacophores for K Na 1.1 inhibition, with the view to treating KCNT1 -associated epilepsy and, with their potencies higher than quinidine, could become key tool compounds to further study this channel. Furthermore, this study illustrates the potential for utilising cryo-electron microscopy in ion channel drug discovery.
Open AccessStructure-based identification and characterisation of novel inhibitors of K Na 1.1 potassium channels, a stratified target for KCNT1 -related epilepsy
Several types of drug-resistant epileptic encephalopathies of infancy have been associated with mutations in the KCNT1 gene, which encodes the sodium-activated potassium channel subunit K Na 1.1. These mutations are commonly gain-of-function, increasing channel activity, therefore inhibition by drugs is proposed as a stratified approach to treat disorders. To date, quinidine therapy has been trialled with several patients, but mostly with unsuccessful outcomes, which has been linked to its low potency and lack of specificity. Here we describe the use of a cryo-electron microscopy-derived K Na 1.1 structure and mutational analysis to identify the quinidine biding site and identified novel inhibitors that target this site using computational methods. We describe six compounds that inhibit K Na 1.1 channels with low- and sub-micromolar potencies, likely through binding in the intracellular pore vestibule. In preliminary hERG inhibition and cytotoxicity assays, two compounds showed little effect. These compounds may provide starting points for the development of novel pharmacophores for K Na 1.1 inhibition, with the view to treating KCNT1 -associated epilepsy and, with their potencies higher than quinidine, could become key tool compounds to further study this channel. Furthermore, this study illustrates the potential for utilising cryo-electron microscopy in ion channel drug discovery.